Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 2.67% is 66% below its 3-year average of 7.79%, near the low end of its 3-year range (2.67%–29.62%).
As of the fiscal period ended Tuesday, June 30, 2026. 31.45% below its 12-month average of 3.90%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 2.67%.
DEBT TO ASSETS RATIO
2.67%
DEBT TO ASSETS RATIO AVG TTM
3.90%
DEBT TO ASSETS RATIO AVG 3Y
5.36%
DEBT TO ASSETS RATIO AVG 5Y
N/A
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-31.45%
CURRENT VS 3Y AVG
-50.14%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 596 covered companies
CURRENT VS SECTOR MEDIAN
+2572.05%
vs the sector median at left
Lexeo Therapeutics, Inc. Common Stock
Market Cap
$250.09M
Debt to Assets Ratio
2.67%
TTM Avg
3.90%
3Y Avg
5.36%
5Y Avg
N/A
Market Cap
$255.42M
Debt to Assets Ratio
0.12%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$244.47M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$255.95M
Debt to Assets Ratio
0.13%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$243.91M
Debt to Assets Ratio
0.68%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$242.25M
Debt to Assets Ratio
0.03%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$259.91M
Debt to Assets Ratio
0.10%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lexeo Therapeutics, Inc. Common Stock (LXEO) | $250.09M | 2.67% | 3.90% | 5.36% | N/A |
| Invivyd, Inc. (IVVD)vs › | $246.20M | 0.04% | N/A | N/A | N/A |
| Century Therapeutics, Inc. (IPSC)vs › | $255.42M | 0.12% | N/A | N/A | N/A |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $244.47M | 0.00% | N/A | N/A | N/A |
| Anika Therapeutics, Inc. (ANIK)vs › | $255.95M | 0.13% | N/A | N/A | N/A |
| Lifecore Biomedical, Inc. (LFCR)vs › | $243.91M | 0.68% | N/A | N/A | N/A |
| AC Immune S.A. (ACIU)vs › | $256.98M | 0.03% | N/A | N/A | N/A |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $242.25M | 0.03% | N/A | N/A | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $259.91M | 0.10% | N/A | N/A | N/A |
| InflaRx N.V. (IFRX)vs › | $240.09M | 0.00% | N/A | N/A | N/A |
Debt/Assets
2.7%
Debt/Equity
0.03
Current Ratio
13.89
Interest Coverage
-530.4x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 2.67% |
| 2026-03-31 | 2.94% |
| 2025-12-31 | 2.94% |
| 2025-09-30 | 5.88% |
| 2025-06-30 | 5.06% |
| 2025-03-31 | 7.48% |
| 2024-12-31 | 6.75% |
| 2024-09-30 | 5.98% |
| 2024-06-30 | 5.65% |
| 2024-03-31 | 5.27% |
| 2023-12-31 | 8.32% |
| 2023-09-30 | 29.62% |
| 2023-06-30 | 19.49% |
| 2023-03-31 | 16.75% |
| 2022-12-31 | 13.89% |
